Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Primmune Therapeutics logo — Engaging Innate Immunity to Cure Cancer

Primmune Therapeutics

Engaging Innate Immunity to Cure Cancer

Founded 2017 United States San Diego, United States 9 employees Series B Total: $56.90M Biotechnology, Health Care

General Information

Company Name Primmune Therapeutics
Founded Year 2017
Location United States San Diego, United States +1
Employees 9
Industries Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when Primmune Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Primmune Therapeutics

Primmune Therapeutics, founded in 2017, is a burgeoning player in the Biotechnology and Health Care industries, headquartered in the United States. Their slogan, "Engaging Innate Immunity to Cure Cancer," underscores their mission to enhance the efficacy of cancer treatments.

The company is pioneering the development of an orally administered TLR7 agonist. This novel approach aims to boost innate immunity, potentially revolutionizing the response rates to both existing and future cancer immunotherapy drugs.

With a recent $8.40M investment during their Series A round on 04 November 2021, Primmune Therapeutics is well-positioned for growth. However, the lack of disclosed investor names might prompt further inquiry into their funding network.

Their focus on innovative solutions in immunotherapy marks them as a significant entity within their field, inviting interest from potential investors keen on healthcare advancements.

Taxonomy: Cancer Immunotherapy, TLR7 Agonist, Innate Immunity, Orally Administered, Medical Research, Patient Response, Immunotherapy Medicines, Cancer Treatment, Biopharmaceutical, Drug Development, Precision Medicine, Oncology, Clinical Trials, Therapeutic Innovation

Services & Products

Development of immune-activating cancer therapies
Clinical-stage biotechnology research
Advancement of oral small-molecule drug design
Conducting Phase 1 clinical trials

Target Customers

Oncologists Cancer patients Pharmaceutical industry partners Investors interested in biotech innovations

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 3
Investor Investor Investor
01 Jan 2026
Series A •••••• - 01 Nov 2021
Series A •••••• 1
Investor
01 Jan 2021
Series A •••••• 7
Investor Investor Investor Investor Investor Investor Investor
01 Oct 2020
Seed •••••• 3
Investor Investor Investor
01 Mar 2020

View All 6 Funding Rounds

Primmune Therapeutics Alternatives & Competitors

Primmune Therapeutics vs
ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd United States

Pioneering immune-based therapies to harness the body's defenses against cancer through advanced imm...

Grant
11 employees
Biotechnology, Health Care
Primmune Therapeutics vs
Alv B AS
Alv B AS Norway

COMPARATIVE ONCOLOGY & IMMUNOTHERAPY

12 employees
Biotechnology
Primmune Therapeutics vs
Sustainable Cell Therapeutics
Sustainable Cell Therapeutics

Pioneering cancer immunotherapy with a focus on patient rehabilitation and treatment of resilient an...

Seed
Biotechnology, Health Care

FAQ About Primmune Therapeutics

Engaging Innate Immunity to Cure Cancer
Primmune Therapeutics was founded in 2017.
Primmune Therapeutics is headquartered in San Diego, United States.
Primmune Therapeutics operates in the following industries: Biotechnology, Health Care.
Primmune Therapeutics has approximately 9 employees.
Primmune Therapeutics has completed 6 funding rounds, raising a total of $56.90M. The latest funding stage is Series B.
Primmune Therapeutics offers: Development of immune-activating cancer therapies, Clinical-stage biotechnology research, Advancement of oral small-molecule drug design, Conducting Phase 1 clinical trials.
Top alternatives and competitors to Primmune Therapeutics include ImmunoCellular Therapeutics Ltd, Alv B AS, Sustainable Cell Therapeutics, Ohana Vaccines, LLC, Immupeutics Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Primmune Therapeutics and ImmunoCellular Therapeutics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Primmune Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy